title: Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT.
abstract: The aim of this study was to determine the efficacy of palonosetron combined with dexamethasone in prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) in patients receiving high-dose (HD)-CT with auto-SCT, and the efficacy of a second dose of palonosetron in treating breakthrough emesis. One hundred thirty-four patients treated with HD-CT and auto-SCT for hematologic malignancies received palonosetron as prophylaxis for CINV on the first day of conditioning; patients were also administered dexamethasone throughout the entire period of conditioning. If breakthrough emesis occurred, a second dose of palonosetron was administered at 72 h after the first administration. Complete response and complete protection were observed in 36 and 26% of patients, respectively. One-half of the patients, re-treated with palonosetron for breakthrough emesis, were successfully rescued. Treatment with palonosetron plus dexamethasone seems to be encouraging in terms of prophylaxis of CINV and treatment of breakthrough emesis in the setting of HD-CT.
authors.affiliation: Oncohaematology and BMT Unit, 'La Maddalena' Oncology Department, Palermo, Italy. mamusso@libero.it
authors.forename: M
authors.initials: M
authors.lastname: Musso
authors.forename: R
authors.initials: R
authors.lastname: Scalone
authors.forename: A
authors.initials: A
authors.lastname: Crescimanno
authors.forename: V
authors.initials: V
authors.lastname: Bonanno
authors.forename: V
authors.initials: V
authors.lastname: Polizzi
authors.forename: F
authors.initials: F
authors.lastname: Porretto
authors.forename: C
authors.initials: C
authors.lastname: Bianchini
authors.forename: T
authors.initials: T
authors.lastname: Perrone
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D000077924:Palonosetron; D011812:Quinuclidines / Q000008:administration & dosage*; D012702:Serotonin Antagonists / Q000008:administration & dosage; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014182:Transplantation, Autologous / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077924:Palonosetron; D003907:Dexamethasone